Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study
Online Appendices
Files in this Data Supplement:
Appendix 1: Minimum fibrosis stage required for reimbursement of simeprevir with peginterferon plus ribavirin for treatment of hepatitis C virus infection in Canadian provinces/territories
Appendix 2: Minimum fibrosis stage required for reimbursement of sofosbuvir with peginterferon and/or ribavirin for treatment of hepatitis C virus infection in Canadian provinces/territories
Appendix 3: Minimum fibrosis stage required for reimbursement of paritaprevir?ritonavir?ombitasvir plus dasabuvir with or without ribavirin for treatment of hepatitis C virus infection in Canadian provinces/ territories
Reviewer Comments
Original Submission
RECORD statement